Company intelligence / Profile preview

EpiVario

Philadelphia, Pennsylvania, United Statesepivario.com ↗

Ownership: Private
Development stage: Preclinical

Overview

EpiVario develops novel small molecule therapeutics that modulate epigenetic processes involved in long-term memory formation. Their lead approach targets the enzyme ACSS2 to disrupt maladaptive memories underlying PTSD and substance use disorders. The company has received NIH grants for preclinical research into treatments for opioid, cocaine, and alcohol use disorder. They have also licensed their portfolio of ACSS2 inhibitor compounds to ReEngage Therapeutics for cancer indications.

Therapeutic areas: PsychiatryNeurology
Modalities: small molecules (specifically neuroepigenetic modulators, ACSS2 inhibitors)
Industry: Biotech

Drug pipeline

2 assets

MTB-9655

1 more asset in the full pipeline.

Partnerships

ReEngage Therapeutics (licensed portfolio of ACSS2 inhibitors for oncology applications)

Beyond the preview

Go deeper on EpiVario.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EpiVario.